BidaskClub upgraded shares of Axovant Sciences Ltd (NYSE:AXON) from a sell rating to a hold rating in a report issued on Thursday morning.

A number of other brokerages also recently commented on AXON. Chardan Capital reiterated a sell rating and issued a $3.00 price objective on shares of Axovant Sciences in a research report on Saturday, September 23rd. UBS AG downgraded Axovant Sciences from an outperform rating to a market perform rating in a research report on Tuesday, September 26th. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $30.00 price objective on shares of Axovant Sciences in a research report on Monday, September 25th. Piper Jaffray Companies downgraded Axovant Sciences from an overweight rating to a neutral rating and reduced their price objective for the stock from $32.00 to $9.00 in a research report on Tuesday, September 26th. Finally, Robert W. Baird downgraded Axovant Sciences from an outperform rating to a neutral rating and reduced their price objective for the stock from $29.00 to $6.00 in a research report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. Axovant Sciences currently has a consensus rating of Hold and an average target price of $14.68.

Shares of Axovant Sciences (NYSE AXON) traded down 10.98% during midday trading on Thursday, hitting $7.05. The stock had a trading volume of 3,431,273 shares. The firm has a 50-day moving average of $16.23 and a 200 day moving average of $16.23. The firm’s market cap is $758.05 million. Axovant Sciences has a 12-month low of $6.13 and a 12-month high of $27.98.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). On average, analysts expect that Axovant Sciences will post ($2.02) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Upgraded to “Hold” at BidaskClub” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-upgraded-to-hold-at-bidaskclub/1613690.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new position in shares of Axovant Sciences in the 2nd quarter worth approximately $696,000. California State Teachers Retirement System increased its holdings in Axovant Sciences by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after purchasing an additional 4,800 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Axovant Sciences by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 3,184 shares in the last quarter. State Street Corp increased its holdings in Axovant Sciences by 52.8% during the 2nd quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after purchasing an additional 188,945 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Axovant Sciences during the 2nd quarter valued at $47,854,000.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.